LEXX · Lexaria Bioscience Corp. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements.”View the 10-Q filed Jul 13, 2026
One customer — 100% of revenue (the nine months ended May 31, 2026)
“In the nine months ended May 31, 2026, the Company recognized revenue of $20,000 on a consolidated basis. One customer accounted for 100% of that total.”
2 customers — 100% of revenue (the nine months ended May 31, 2025)
“In the nine months ended May 31, 2025, the Company recognized revenue of $531,923 on a consolidated basis. Two customers accounted for 100% of that total.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $194K | $705.92K | $464.28K | $226.21K | $255.4K | $722.74K | $314.79K | $222.61K | $433.29K | $63.64K | $40.72K | — | — | — | — | — | |
| — | — | $14.31K | $43.19K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | $43.19K | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| $0 | $2720 | $4822 | $31.5K | $71.84K | $175.35K | $99.38K | $22.89K | $25.19K | $29.75K | $45.62K | $29.88K | $0 | $795.2K | $783.27K | $667.86K | |
| $194K | $703.2K | $459.46K | $194.71K | $183.56K | $547.39K | $215.42K | $199.72K | $408.1K | $33.89K | -$4897 | -$15.18K | $0 | $302.25K | $574.49K | $465.91K | |
| — | 99.61% | 98.96% | 86.07% | 71.87% | 75.74% | 68.43% | 89.72% | 94.19% | 53.25% | -12.03% | — | — | — | — | — | |
| $4M | $8.24M | $2.36M | $3.67M | $1.84M | $1.26M | $387.07K | $555.73K | $492.86K | $54.19K | $9024 | $146.47K | $0 | — | — | — | |
| $3.9M | $4.35M | $3.85M | $3.06M | $4.96M | $4.97M | $3.98M | $297.21K | $217.66K | $129.73K | $133.68K | $18.83K | $11.63K | $6755 | $2966 | $5181 | |
| — | $36.6K | — | — | — | $6870 | $6772 | $4393 | $1688 | $869 | — | — | — | — | — | — | |
| $24.73K | $51.23K | $42.45K | $145.4K | $102.72K | $111.72K | — | — | — | — | — | — | — | — | — | — | |
| $7.9M | $12.58M | $6.21M | $6.73M | $6.8M | $6.23M | $4.36M | $4.36M | $7.02M | $1.96M | $1.27M | $1.97M | $1.56M | $645.8K | $826K | $1M | |
| -$7.71M | -$11.88M | -$5.75M | -$6.53M | -$6.62M | -$5.69M | — | — | — | — | -$1.28M | -$1.98M | -$1.56M | — | — | — | |
| — | -1683.01% | -1239.16% | -2888.5% | -2591.67% | -786.85% | — | — | — | — | -3136.82% | — | — | — | — | — | |
| -$7.68M | -$11.83M | -$5.71M | -$6.39M | -$6.52M | -$5.58M | — | — | — | — | — | — | — | — | — | — | |
| $1125 | — | — | — | — | — | — | — | — | $6015 | $2250 | $31.54K | $165.79K | $267.36K | $237.64K | $223.67K | |
| -$28.11K | -$30.7K | -$55.52K | -$178.5K | -$764.61K | — | — | — | — | — | — | — | — | — | — | — | |
| — | $33.54K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$11.91M | -$5.81M | -$6.71M | -$7.38M | -$4.17M | -$3.99M | -$4.16M | -$6.61M | -$1.93M | -$1.27M | — | — | — | — | — | |
| — | — | — | — | $0 | $6093 | $2319 | $17.66K | $0 | $0 | $0 | — | — | — | — | — | |
| -$7.73M | -$11.9M | -$5.8M | -$6.66M | -$7.27M | -$4.03M | -$4.08M | $4.1M | $6.6M | -$1.93M | -$1.28M | -$1.98M | -$1.56M | — | — | -$538.23K | |
| — | -1686% | -1248.25% | -2946.36% | -2846.28% | -557.19% | -1297.56% | 1841.79% | 1523.24% | -3031.89% | -3136.82% | — | — | — | — | — | |
| -$8418 | -$9593 | -$13.31K | -$47.63K | -$114.33K | -$159.14K | -$150.62K | -$58.99K | -$10.34K | -$60.19K | -$62.48K | -$163.85K | $0 | — | — | — | |
| -$7.03M | — | — | — | -$7.27M | -$4.03M | -$3.93M | -$4.1M | -$6.61M | -$1.87M | -$1.21M | -$1.77M | $0 | — | — | — | |
| -$7.7M | -$11.95M | -$5.82M | -$6.66M | — | — | — | — | -$6.62M | -$1.93M | -$1.28M | -$1.77M | — | -$343.55K | -$251.51K | -$538.23K | |
| USD/shares | -$5.25 | -$9.90 | -$7.05 | -$15.15 | — | — | — | — | — | — | — | — | — | — | — | -$0.60 |
| shares | — | — | — | — | — | 292.76K | 184.89K | 5.19M | 4.73M | 3.92M | 2.92M | 2.65M | 1.56M | 1.1M | 1.1M | — |
| shares | — | 1.2M | 825.6K | 440.94K | — | 292.76K | 184.89K | 5.19M | 4.73M | 3.92M | 2.92M | 2.65M | 1.56M | 1.1M | 1.1M | 945.1K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-05-31 | USD 86,714 | 10-Q filed 2026-07-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 174 similar-size Biotechnology companies (of 559 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Intellectual Property Licensing | $696,000 | $457,990 | $146,800 | $54,560 | $334,974 | — |
| Consolidated Total | — | — | — | — | $722,738 | $384,543 |
| Intellectual Property Licensing | — | — | — | — | $334,974 | $232,909 |
| Rand D | — | — | — | $54,800 | — | — |
| Corporate | — | $0 | $0 | $32,599 | $90,485 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| IP Licensing | $696,000 | $457,990 | — | — | — | — |
| BTwo B | $9,923 | $5,388 | — | — | — | — |
| Other Revenue | $0 | $900 | — | — | — | — |
| B2 B | — | — | — | — | $297,279 | $151,634 |
| R and D | — | $900 | $35,241 | $54,800 | — | — |
| Product | — | — | — | $113,438 | $297,279 | — |